{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T22:10:20Z","timestamp":1781561420679,"version":"3.54.5"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease. Research on the efficacy of probiotics, prebiotics, and synbiotics on NAFLD patients continues to be inconsistent. The purpose of this study is to evaluate the effectiveness of these microbial therapies on NAFLD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Eligible randomized-controlled trials reporting the effect of probiotics, prebiotics, or synbiotics in NAFLD were searched in PubMed, Web of Science, Embase, Google scholar, and CNKI databases from 2020 to Jul 2022. The changes in the outcomes were analyzed using standard mean difference (SMD) and 95% confidence intervals (CIs) with a random- or fixed-effects model to examine the effect of microbial therapies. Subgroup analysis, influence and publication bias analysis were also performed. The quality of the eligible studies was evaluated using the Cochrane Risk of Bias Tool.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eleven studies met the inclusion criteria involving 741 individuals. Microbial therapies could improve liver steatosis, total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL-c), alanine aminotransferase (ALT), alkaline phosphatase (ALP), glutamyl transpeptidase (GGT), and homeostasis model assessment-insulin resistance (HOMAI-R) (all <jats:italic>P<\/jats:italic> &amp;lt; 0.05). But microbial therapies could not ameliorate body mass index (BMI), energy, carbohydrate, fat intake, fasting blood sugar, HbA1c, insulin, high-sensitivity C-reactive protein (hs-CRP), and hepatic fibrosis of patients with NAFLD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Probiotics, prebiotics, and synbiotics supplementation can potentially improve liver enzymes, lipid profiles, and liver steatosis in patients with NAFLD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnut.2022.1024678","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T06:38:56Z","timestamp":1666679936000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["The effects of supplementation of probiotics, prebiotics, or synbiotics on patients with non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"9","author":[{"given":"Wenmin","family":"Xing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenlei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genxiang","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuyong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.923599","article-title":"The role of gut microbiota in some liver diseases: from an immunological perspective.","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101333","article-title":"Non-alcoholic fatty liver disease, heart failure, and long-term mortality: insights from the national health and nutrition examination survey.","volume":"47","author":"Minhas","year":"2022","journal-title":"Curr Probl Cardiol."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnac018","article-title":"Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease.","author":"Yabut","year":"2022","journal-title":"Endocr Rev."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32708","article-title":"Hepatocyte Ltb4r1 promotes NAFLD development in obesity.","author":"Liu","year":"2022","journal-title":"Hepatology."},{"key":"B5","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nrgastro.2016.85","article-title":"The role of the gut microbiota in NAFLD.","volume":"13","author":"Leung","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B6","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/apt.13376","article-title":"Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease.","volume":"42","author":"Wieland","year":"2015","journal-title":"Aliment Pharmacol Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.cct.2018.05.010","article-title":"Design and rationale of the INSYTE study: a randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal microbiota in non-alcoholic fatty liver disease.","volume":"71","author":"Scorletti","year":"2018","journal-title":"Contemp Clin Trials."},{"key":"B8","doi-asserted-by":"publisher","first-page":"8594","DOI":"10.1039\/d1fo00448d","article-title":"Co-supplementation of camelina oil and a prebiotic is more effective for in improving cardiometabolic risk factors and mental health in patients with NAFLD: a randomized clinical trial.","volume":"12","author":"Kavyani","year":"2021","journal-title":"Food Funct."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/nu13093192","article-title":"The effect of probiotics (MCP(\u00ae) BCMC(\u00ae) Strains) on hepatic steatosis, small intestinal mucosal immune function, and intestinal barrier in patients with non-alcoholic fatty liver disease.","volume":"13","author":"Mohamad Nor","year":"2021","journal-title":"Nutrients."},{"key":"B10","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/jn\/nxab392","article-title":"A specifically tailored multistrain probiotic and micronutrient mixture affects nonalcoholic fatty liver disease-related markers in patients with obesity after mini gastric bypass surgery.","volume":"152","author":"Crommen","year":"2022","journal-title":"J Nutr."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.846873","article-title":"Probiotic therapy with VSL#3(\u00ae) in patients with NAFLD: a randomized clinical trial.","volume":"9","author":"Derosa","year":"2022","journal-title":"Front Nutr."},{"key":"B12","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3345\/cep.2021.00787","article-title":"Effects of probiotics combined with dietary and lifestyle modification on clinical, biochemical, and radiological parameters in obese children with nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis: a randomized clinical trial.","volume":"65","author":"Rodrigo","year":"2022","journal-title":"Clin Exp Pediatr."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.931458","article-title":"Dietary component-induced inflammation and its amelioration by prebiotics, probiotics, and synbiotics.","volume":"9","author":"Bilal","year":"2022","journal-title":"Front Nutr."},{"key":"B14","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature09646","article-title":"Bifidobacteria can protect from enteropathogenic infection through production of acetate.","volume":"469","author":"Fukuda","year":"2011","journal-title":"Nature."},{"key":"B15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.clnesp.2020.06.020","article-title":"The effects of Bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: a randomized, placebo-controlled, clinical trial.","volume":"39","author":"Abhari","year":"2020","journal-title":"Clin Nutr ESPEN."},{"key":"B16","doi-asserted-by":"crossref","first-page":"1597.e","DOI":"10.1053\/j.gastro.2020.01.031","article-title":"Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease.","volume":"158","author":"Scorletti","year":"2020","journal-title":"Gastroenterology."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1007\/s00394-017-1568-y","article-title":"Effect of probiotics and synbiotics consumption on serum concentrations of liver function test enzymes: a systematic review and meta-analysis.","volume":"57","author":"Khalesi","year":"2018","journal-title":"Eur J Nutr."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1111\/1750-3841.15367","article-title":"Effects of probiotic and prebiotic supplementation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease: a randomized clinical trial.","volume":"85","author":"Behrouz","year":"2020","journal-title":"J Food Sci."},{"key":"B19","doi-asserted-by":"crossref","DOI":"10.1177\/1756284819878046","article-title":"Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis.","volume":"12","author":"Tang","year":"2019","journal-title":"Therap Adv Gastroenterol."},{"key":"B20","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1080\/17474124.2022.2016391","article-title":"Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis.","volume":"15","author":"Yang","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol."},{"key":"B21","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1007\/s10620-019-05699-z","article-title":"Efficacy of probiotics and synbiotics in patients with nonalcoholic fatty liver disease: a meta-analysis.","volume":"64","author":"Liu","year":"2019","journal-title":"Dig Dis Sci."},{"key":"B22","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1080\/10408398.2018.1458021","article-title":"Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of clinical trials: synbiotic supplementation and NAFLD.","volume":"59","author":"Hadi","year":"2019","journal-title":"Crit Rev Food Sci Nutr."},{"key":"B23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5005\/jp-journals-10018-1233","article-title":"Role of probiotics in the treatment of nonalcoholic fatty liver disease: a meta-analysis.","volume":"7","author":"Lavekar","year":"2017","journal-title":"Euroasian J Hepatogastroenterol."},{"key":"B24","doi-asserted-by":"crossref","first-page":"391","DOI":"10.4093\/dmj.2022.0048","article-title":"Lifestyle interventions for non-obese patients both with, and at risk, of non-alcoholic fatty liver disease.","volume":"46","author":"Zhang","year":"2022","journal-title":"Diabetes Metab J."},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ."},{"key":"B26","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/1357633X20959581","article-title":"Telemedicine intervention-reduced blood pressure in a chronic disease population: a meta-analysis.","volume":"28","author":"Gao","year":"2020","journal-title":"J Telemed Telecare."},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021464","article-title":"Protective effect of probiotics in patients with non-alcoholic fatty liver disease.","volume":"99","author":"Cai","year":"2020","journal-title":"Medicine (Baltimore)."},{"key":"B29","first-page":"82","article-title":"The effect of gerilact on non-alcoholic fatty liver disease.","volume":"27","author":"Sadrkabir","year":"2020","journal-title":"J Kerman Univ Med Sci."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-021-01660-5","article-title":"A randomised placebo controlled trial of VSL#3(\u00ae) probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease.","volume":"21","author":"Chong","year":"2021","journal-title":"BMC Gastroenterol."},{"key":"B31","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1016\/j.jacc.2013.11.004","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines and the obesity society.","author":"Jensen","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017995","article-title":"Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials.","volume":"9","author":"Koutnikova","year":"2019","journal-title":"BMJ Open."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.935714","article-title":"Polysaccharide, the Active Component of Dendrobium officinale, ameliorates metabolic hypertension in rats via regulating intestinal flora-SCFAs-vascular axis.","volume":"13","author":"Li","year":"2022","journal-title":"Front Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.916271","article-title":"Hypoglycemic effects of Lycium barbarum polysaccharide in Type 2 diabetes mellitus mice via modulating gut microbiota.","volume":"9","author":"Ma","year":"2022","journal-title":"Front Nutr."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.927883","article-title":"Efficacy of dietary supplements targeting gut microbiota in the prevention and treatment of gestational diabetes mellitus.","volume":"13","author":"Wan","year":"2022","journal-title":"Front Microbiol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/ejcn.2012.103","article-title":"The influence of probiotic supplementation on gut permeability in patients with metabolic syndrome: an open label, randomized pilot study.","volume":"66","author":"Leber","year":"2012","journal-title":"Eur J Clin Nutr."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00029","article-title":"Impact of gut microbiota on host glycemic control.","volume":"10","author":"Gerard","year":"2019","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.2337\/diabetes.53.10.2623","article-title":"Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study.","volume":"53","author":"Hanley","year":"2004","journal-title":"Diabetes."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.900652","article-title":"Therapeutic effect of fecal microbiota transplantation on chronic unpredictable mild stress-induced depression.","volume":"12","author":"Cai","year":"2022","journal-title":"Front Cell Infect Microbiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1111\/jcmm.16229","article-title":"Val-Val-Tyr-Pro protects against non-alcoholic steatohepatitis in mice by modulating the gut microbiota and gut-liver axis activation.","volume":"25","author":"Xie","year":"2021","journal-title":"J Cell Mol Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.ijbiomac.2022.07.100","article-title":"Oyster (Crassostrea gigas) polysaccharide ameliorates obesity in association with modulation of lipid metabolism and gut microbiota in high-fat diet fed mice.","volume":"216","author":"Ma","year":"2022","journal-title":"Int J Biol Macromol."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.927245","article-title":"Akkermansia muciniphila enhances egg quality and the lipid profile of egg yolk by improving lipid metabolism.","volume":"13","author":"Wei","year":"2022","journal-title":"Front Microbiol."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063388","article-title":"Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut-liver axis.","volume":"8","author":"Endo","year":"2013","journal-title":"PLoS One."},{"key":"B44","doi-asserted-by":"publisher","first-page":"130","DOI":"10.12938\/bmfh.2021-057","article-title":"Lactococcus lactis subsp. cremoris C60 induces macrophages activation that enhances CD4+ T cell-based adaptive immunity.","volume":"41","author":"Saito","year":"2022","journal-title":"Biosci Microbiota Food Health."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2022.2108655","article-title":"The double-edged sword of probiotic supplementation on gut microbiota structure in Helicobacter pylori management.","volume":"14","author":"Nabavi-Rad","year":"2022","journal-title":"Gut Microbes."},{"key":"B46","doi-asserted-by":"crossref","first-page":"10194","DOI":"10.1021\/acs.jafc.2c03639","article-title":"Alternative to sugar, honey does not provoke insulin resistance in rats based on lipid profiles, inflammation, and IRS\/PI3K\/AKT signaling pathways modulation.","volume":"70","author":"Chen","year":"2022","journal-title":"J Agric Food Chem."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.930626","article-title":"Association of gut microbiota with sort-chain fatty acids and inflammatory cytokines in diabetic patients with cognitive impairment: a cross-sectional, non-controlled study.","volume":"9","author":"Du","year":"2022","journal-title":"Front Nutr."},{"key":"B48","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.tem.2022.07.001","article-title":"Immune-metabolic interactions in homeostasis and the progression to NASH.","volume":"33","author":"Hoogerland","year":"2022","journal-title":"Trends Endocrinol Metab."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1186\/s13293-020-00346-z","article-title":"Analysis of sex differences in dietary copper-fructose interaction-induced alterations of gut microbial activity in relation to hepatic steatosis.","volume":"12","author":"Song","year":"2021","journal-title":"Biol Sex Differ."},{"key":"B50","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/ajpa.23842","article-title":"Gut microbiome composition of wild western lowland gorillas is associated with individual age and sex factors.","volume":"169","author":"Pafco","year":"2019","journal-title":"Am J Phys Anthropol."}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2022.1024678\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T06:39:13Z","timestamp":1666679953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2022.1024678\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,25]]},"references-count":50,"alternative-id":["10.3389\/fnut.2022.1024678"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2022.1024678","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,25]]},"article-number":"1024678"}}